Geovax Labs Inc (GOVX) 0.1250 $GOVX GeoVax Ebola Vaccine

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Geovax Labs Inc (GOVX) 0.1250 $GOVX

GeoVax Ebola Vaccine Proven Effective in Rodent Models
Marketwired - Tue Sep 08, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel platform technology, announced today that its investigational Ebola vaccine candidate, GOVX-E301, provided 100 percent protection in guinea pigs and Syrian golden hamsters, two rodent models for Ebolavirus infections. The GOVX-E301 vaccine uses a recombinant modified vaccinia Ankara (MVA) vector to express non-infectious virus-like particles (VLPs) using genetic sequences from the 2014 Ebolavirus outbreak in West Africa. The studies were conducted in collaboration with, and funded in part by, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

GeoVax Reports 2015 Second Quarter Financial Results and Provides Corporate Update
Marketwired - Tue Aug 04, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel platform technology, announced its financial results for the three and six months ended June 30, 2015 and provided the following corporate update.

Ebola Viral Infections Therapeutics Pipeline Review, H1 2015 - 30 Companies & 61 Drug Profiles
M2 - Thu Jul 09, 6:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qdd37g/ebola_viral) has announced the addition of the "Ebola Viral Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ebola Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ebola Viral Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Abivax S.A. - AmVac AG - AnGes MG, Inc. - Canopus BioPharma Incorporated - Crucell N.V. - Etubics Corporation - FIT Biotech Oy - GeoVax Labs, Inc. - GlaxoSmithKline plc - Hemispherx Biopharma, Inc. - Humabs BioMed SA - Immune Response BioPharma, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Kymab Limited - Medicago Inc. - Merck & Co., Inc. - Microbiotix, Inc. - Navigen Pharmaceuticals, Inc. - Novavax, Inc. - Peregrine Pharmaceuticals, Inc. - SignPath Pharma Inc - Sihuan Pharmaceutical Holdings Group Ltd. - SKAU Vaccines ApS - Tamir Biotechnology, Inc. - Tekmira Pharmaceuticals Corp. - Toyama Chemical Co., Ltd. - United Therapeutics Corporation - Vaxart, Inc. - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/qd...bola_viral
UTHR: 123.59 (-1.69), TKMR: 10.83 (+0.58), GSK: 40.22 (+0.06), INO: 6.16 (+0.20), NVAX: 8.04 (+0.43), MRK: 50.95 (-0.07)

GeoVax Receives Grant From NIH for HIV Vaccine Program
Marketwired - Wed Jul 01, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, announced today it has received a Notice of Award from the U.S. National Institutes of Health for a Small Business Innovative Research (SBIR) grant in support of its clade C HIV vaccine development program for Africa. The grant award of $299,585 is for the first year of a two-year project period beginning July 1, 2015.

AFRICAN LEADERSHIP MAGAZINE to Present Two Prestigious Awards to GeoVax and Dr. Robert McNally
Marketwired - Thu Jun 25, 4:45PM CDT
GeoVax Labs, Inc. (OTCQB: GOVX) announced today that Robert McNally Ph.D., President & CEO, will receive the African Health Impact Award from The African Leadership Magazine during a ceremony to be held Friday, June 26th at 6:30 pm. He will also be inducted into the African Leadership Hall of Fame. The award recognizes GeoVax's significant ongoing role in the fight against HIV/AIDS and Ebola in Africa and its commitment to helping curb epidemics in the African continent.

GeoVax to Present at the LD Micro Invitational Conference
Marketwired - Wed May 27, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola virus and HIV using its novel platform technology, today announced that it will present at the LD Micro Invitational Conference on June 1, 2015 at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company's presentation by Dr. Robert T. McNally, President and CEO, is scheduled to begin at 2:00PM PDT. Management will also be available during the conference for one-on-one meetings.

GeoVax to Present at the 2015 Marcum MicroCap Conference
Marketwired - Tue May 19, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola virus and HIV using its novel platform technology, today announced that it will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015 in New York City at the Grand Hyatt Hotel.

Global HIV Vaccine Market Future Outlook 2015
M2 - Mon May 18, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cqfn9x/global_hiv) has announced the addition of the "Global HIV Vaccine Market Future Outlook" report to their offering. Pharmaceutical companies have recognized the dearth of effective HIV medications due to which they are investing significant amount on research and development of HIV vaccines. Various candidates are at different stages of clinical trials and they would be introduced in market in coming years. Technology is developing at rapid rates due to which screening of selected candidate is expected to take place at lesser time. In this way, market winding times are expected to decrease due to lesser time in developmental phases. Manufacturing capabilities are highly developed but some tweaking has to be done according to HIV pathogen. Significant development in recombinant DNA technology and genetic engineering is also expected to accelerate the rate of HIV vaccine development. Investigators are also expected to find new modalities that will help in checking the AIDS. In this way, future of HIV vaccines market looks optimistic and it may be commercialized in next 5-10 years. "Global HIV Vaccine Market Future Outlook" Report Highlights: - Introduction to HIV Vaccines - Issues Related to the Development of HIV Vaccines - Parameters for Successful Commercialization of HIV Vaccines - Global HIV Vaccines Market Opportunity Analysis - Global HIV Vaccine Clinical Pipeline by Company & Phase - Global HIV Vaccine Clinical Pipeline: 100 Vaccines - Majority Vaccine in Preclinical Phase: 42 Vaccines Companies Mentioned - AlphaVax - Antigen Express - Argo Therapeutics - Bionor Pharmaceuticals - Celldex Therapeutics - FIT Biotech - Crucell Pharmaceutical - GeneCure - Genetic Immunity - GenVec - GeoVax Labs - Glaxo Smithkline - Immune Response BioPharma - Inovio Pharmaceuticals - Novartis - Oncolys Biopharma - PaxVax - Profectus Biosciences - Sanofi - TVAX Biomedical For more information visit http://www.researchandmarkets.com/research/cqfn9x/global_hiv
INO: 6.16 (+0.20), CLDX: 12.80 (+1.06), NVS: 91.90 (-0.71)

GeoVax Reports 2015 First Quarter Financial Results and Provides Corporate Update
Marketwired - Wed May 13, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the three months ended March 31, 2015, and provided the following corporate update.

Liberia declared Ebola-free
Seeking Alpha - at Seeking Alpha - Sun May 10, 6:06AM CDT

BCRX: 8.80 (-0.95), VSR: 3.34 (-0.06), TKMR: 10.83 (+0.58), GSK: 40.22 (+0.06), NNVC: 1.35 (-0.05), JNJ: 95.37 (+0.29), INO: 6.16 (+0.20), CMRX: 37.40 (-0.19), APT: 2.11 (unch), HEB: 0.16 (unch), SRPT: 37.09 (-0.72), SMED: 9.32 (+0.03), NLNK: 34.31 (+1.42), PLX: 1.13 (-0.01), LAKE: 13.59 (-0.28), NSPH: 2.07 (+0.08)

GeoVax Path Forward Coming Into Focus
Jason Napodano, CFA - at Seeking Alpha - Wed Apr 22, 10:15AM CDT


GeoVax Enters Into Research Collaboration Agreement With the NIH for Ebola/Marburg Vaccines
Marketwired - Thu Apr 16, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced that it has entered into a Research Collaboration Agreement (the "Agreement" with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for development of GeoVax's vaccines against Ebola and Marburg viruses.

GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine
Marketwired - Tue Apr 14, 8:02AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today announced its intention to pursue a dual pathway for advancing its preventive clade B HIV vaccine into pivotal human efficacy trials.

GeoVax Provides Details of Presentation at World Vaccine Congress
Marketwired - Thu Apr 09, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today provided details of the talk presented by its Chief Scientific Officer, Harriet L. Robinson, Ph.D., at the World Vaccine Congress in Washington, D.C. The title of her talk was, "Phase 2 Development of a Prophylactic HIV Vaccine."

GeoVax Labs Issues Letter to Shareholders
Marketwired - Mon Apr 06, 9:30AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and Marburg viruses, and HIV using its novel platform technology, has provided shareholders with an annual update letter. The letter is distributed in GeoVax's 2014 Annual Report to Shareholders mailed on April 2, and can be read in full by visiting the following link: http://www.geovax.com/investors.html

GeoVax Provides Update on Its HIV Vaccine Program
Marketwired - Wed Apr 01, 9:30AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV, today announced that the HIV Vaccine Trials Network (HVTN) has assigned a trial number, HVTN 114, to the next clinical trial of its clade B preventive HIV vaccine candidate.

GeoVax's Chief Scientific Officer to Speak at World Vaccine Congress
Marketwired - Tue Mar 31, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today announced that Chief Scientific Officer Dr. Harriet L. Robinson, is invited to speak at the World Vaccine Congress to be held April 7-9, 2015 in Washington, DC. Dr. Robinson is scheduled to speak on April 8, 2015. The title of her talk is "Phase 2 Development of a Prophylactic HIV Vaccine."

GeoVax Appoints Industry Veteran to Its Board of Directors
Marketwired - Mon Mar 23, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola and Marburg viruses, and HIV using its novel platform technology, today announced that it has appointed vaccine industry expert, Randal D. Chase, Ph.D. to its board of directors. This appointment brings the number of board members to six, four of whom are considered independent.
NVX: 15.09 (-0.01)

GeoVax Reports 2014 Year-End Financial Results
Marketwired - Fri Mar 20, 8:22AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2014, and provided the following corporate update.

GeoVax Provides Progress Report on Its Ebola Vaccine Program
Marketwired - Mon Jan 12, 8:01AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its unique vaccine delivery platform, today provided an update on its Ebola virus vaccine development program.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 108

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 58

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 57

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 122

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 39

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Rock & Roll Hall of Fame's 2026 Induction Triumph

Updated Category News Views 90

A Night of Unstoppable Talent The Rock & Roll Hall of Fame's 2026 Induction Ceremony and boy, what a spectacle it was. Held on a lively Saturday night, November 14, in Los Angeles, it wasn't just an event; it was an electrifying testament to music's profound impact. With the grand ceremony kicking off at the historic city of stars, this year's induction turned the dial to...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 17

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 94

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 39

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading

Top 5 Most Recently Viewed Articles

Warren Buffett's Wisdom: Rethinking Your Stock Strategy

Updated Category News Views 155

Billionaire investor Warren Buffett became a titan in finance through his distinctive approach to stock investing, one that flips conventional wisdom on its head. While most folks lose their heads when prices drop, Buffett sees opportunity. When stocks go down, he doesn’t cry; he gets excited. "I love it when the things we buy go down," he said in a reflective moment...

Continue Reading
Kenneth L Calloway's $452K Share Sale: What It Means for CENX

Updated Category News Views 220

Understanding the Recent Insider Trade in Century Aluminum In a notable move that has caught the attention of investors, Kenneth L Calloway, the Senior Vice President at Century Aluminum, recently sold a significant amount of stocks. The transaction, which took place recently and is detailed in an SEC filing, involved the sale of 16,450 shares valued at approximately...

Continue Reading
Jura Energy Corporation Releases Key Financial Information

Updated Category News Views 213

Jura Energy Corporation Financial Filings Overview Jura Energy Corporation has recently announced an important update regarding its financial performance. The company has filed its condensed consolidated interim financial statements for the periods ending June 30 for both 2025 and 2024 on SEDAR. Alongside these financial statements, Jura has also released its...

Continue Reading
Exploring the Surge in Edge Computing Growth and Its Impact

Updated Category News Views 207

Understanding Edge Computing Growth Dynamics The edge computing market is poised for significant growth, projected to increase by USD 19.6 billion during the period between 2024 and 2028. This advancement is primarily fueled by the rising demand for decentralized computing, aimed at minimizing latency in decision-making processes. Technological advancements heralding...

Continue Reading
Hiab's Q3 Report 2025: Navigating Challenges with Resilience

Updated Category News Views 239

Hiab's Financial Journey in Q3 2025: An Overview Hiab's latest quarterly report sheds light on the company's performance amidst swirling market uncertainties. The recent challenges stemmed primarily from lower sales figures in parts of their market, particularly in the United States, affecting profitability. Key Highlights of the Quarterly Performance The first major...

Continue Reading